Clinical software rarely stays at the edge of patient care for long. A documentation aid, evidence search tool, or AI clinical decision support platform may begin as a “quick lookup” and later sit beside the EHR, the pharmacy workflow, or a primary care team’s inbox. That progression is why privacy due diligence belongs in the purchasing conversation, not after go-live. The goal is not to treat every vendor as suspect; it is to make data flows, contractual obligations, and clinician responsibilities visible before patient information enters a new system. For physicians, hospitalists, family physicians, pharmacists, and advanced practice clinicians, the most useful questions are concrete, documented, and tied to real workflows.
Start With How Patient Data Moves Through the System
Begin with a map, not a feature list. Ask the vendor what data the product receives, stores, processes, and transmits, and whether the clinician can use the tool without entering protected health information at all. A clinical evidence search tool may be designed for de-identified questions, while an EHR-adjacent workflow may involve identifiers, encounter context, or medication lists. The answer matters because the minimum necessary standard should shape both configuration and daily use. Clinicians should know whether they can disable history, whether prompts are retained, and whether free-text questions are logged in a way that could later be linked to a patient or user.
Ask specifically about prompts, outputs, logs, backups, and analytics. AI-enabled tools can create new data categories: the question a clinician types, the answer generated, the citations returned, and the feedback a user provides. The vendor should explain retention periods, deletion controls, and whether any of that content is used for product improvement, model training, or quality analytics. If the answer is “aggregated” or “de-identified,” ask for the method and the contractual limits. Also ask where data is hosted, who can access it, how access is approved, and whether audit logs are available to the covered entity. Encryption in transit and at rest, role-based permissions, and incident response are baseline topics, but the clinician-facing question is simpler: what patient information is necessary, where does it go, and how is it removed?
Do not overlook mobile and tablet use, browser extensions, copy-paste habits, and single sign-on. A tool can be secure in theory yet awkward enough that busy teams paste notes into the wrong window. Ask for a short workflow demonstration using non-PHI examples, and ask whether the vendor provides training on safe use. If the product offers clinical evidence search with citations, confirm whether search history is personal, shared, or exportable. These details help primary care teams and hospitalists decide whether the tool belongs in an approved workflow or should remain a reference-only resource. The point is not to slow adoption; it is to avoid discovering a data flow after it has already become routine.
Get Specific About the Business Associate Agreement
A Business Associate Agreement, or BAA, is not a checkbox at the end of procurement. It is the written instrument that should align with the actual service. Ask whether the vendor will sign a BAA before any PHI is exchanged, and ask who reviews it on their side. If the vendor says a BAA is unnecessary because the product is “just a search tool,” ask them to explain in writing why PHI will never be received. The covered entity’s privacy officer and legal counsel should make that determination, not a sales deck. For clinicians, the practical question is whether the vendor understands the difference between a reference lookup and a workflow that touches identifiable patient data.
Read the BAA for permitted uses and disclosures, not just signatures. Does it limit the vendor’s use of PHI to the services described? Does it prohibit secondary use for model training, marketing, or unrelated analytics? Does it require subcontractors to meet the same obligations, and does it list any subcontractors that will touch PHI? Ask how the vendor handles breach notification, including timelines, escalation contacts, and who communicates with affected clinicians. Ask about return or destruction of data at termination, including backups and derived logs. If the service includes AI-generated answers or third-party model providers, ask whether those parties are covered by the BAA and whether their data handling is described in the contract.
Also ask about audit rights, security incident reporting, insurance, and termination assistance. A BAA should be concrete enough that a privacy officer can trace a data element from entry to deletion. Clinicians do not need to negotiate every clause, but they should ask whether the agreement covers the exact module being purchased, the mobile app, and any future features that may process PHI. If the vendor offers a standard BAA, request a copy early and route it to privacy and legal review. A vendor that answers these questions clearly is easier to evaluate than one that relies on broad assurances. The aim is a shared understanding: the covered entity remains responsible for HIPAA compliance, and the business associate must support that responsibility in writing.
Pressure-Test AI, Citations, and EHR-Centred Workflows
AI clinical decision support can be useful precisely because it is fast, but speed is not a privacy control. Ask how the system generates answers, what source materials it retrieves, and whether citations are traceable to peer-reviewed journals, guidelines, or other primary sources. Ask whether users can see source dates, publication types, and the exact passage behind a claim. These questions are not only about accuracy; they also affect whether clinicians can verify an answer before acting. AI supports, and does not replace, clinical judgment. Any answer should be checked against the cited primary sources, especially when the question involves medication dosing, interactions, or complex multimorbidity.
Ask how the tool fits an EHR-centred workflow. Does it require copying patient details into a separate browser tab? Can users search with de-identified terms? Are prompts and answers stored in the EHR, the vendor platform, or both? If the product integrates with an EHR, ask how access is authorized, whether role-based permissions carry over, and what audit trail exists. If it does not integrate, ask how the vendor prevents accidental PHI entry and whether a “private search” mode is available. For pharmacists reviewing interactions or primary care teams checking guideline changes, the safest workflow is often the one that minimizes duplicate data entry and keeps patient context inside approved systems.
Finally, ask for a security and privacy review packet, a non-PHI demonstration, and written answers to your questions. For teams evaluating a platform intended to support HIPAA compliant medical workflows, the same due diligence applies: review the BAA, document the intended use, and test the tool with non-PHI examples. Some clinicians may trial ZoeMD or another evidence retrieval platform for cited clinical answers; the vendor conversation should still cover data retention, model training, subcontractors, and deletion. The strongest position is not to assume risk is absent, but to know exactly who handles patient information, under what contract, and with what clinician oversight.
